When investors hear talk of 'big pharma' it's easy to picture behemoths such as AstraZeneca (AZN) and GlaxoSmithKline (GSK) - stalwarts of the FTSE 100 for years. But, on closer inspection, the four big pharma constituents in that index (five if you count medical equipment company Smith & Nephew (SN.)) have never looked more different.
To continue reading, register today
to enjoy limited access to the following:
- Daily trading news
- Funds coverage
- Features on big investment themes
- Comprehensive companies coverage
- Economic analysis